Baggio–Yoshinari syndrome

Baggio–Yoshinari syndrome
Other namesBrazilian Lyme Disease-like illness; Brazilian Human Borreliosis
Amblyomma cajennense
Amblyomma cajennense can transmit the condition
SpecialtyInfectious disease;

Rheumatology;

Neurology.
SymptomsFever;

enlarged lymph nodes; Headache; Erythema migrans; Meningoencephalitis; Arthritis; Fatigue ; Cognitive dysfunction;

Autoimmune dysfunction.
Diagnostic methodClinical and laboratory signs
Differential diagnosisSystemic lupus erythematous;

Rheumatoid arthritis; Chronic fatigue syndrome; Leptospirosis; Syphilis; Multiple sclerosis;

Fibromyalgia.
TreatmentAntibiotics (doxycycline and ceftriaxone)
FrequencyUnknown

Baggio–Yoshinari syndrome (BYS), formerly known as the Brazilian Lyme disease-like illness (BLDLI) and Brazilian Human Borreliosis, is an anthropozoonotic infectious disease of infectious-reactional character transmitted by bites of ticks from Amblyomma, Rhipicephalus and Dermacentor[1] genera, that clinically resembles the Lyme Disease (LD) seen in the northern hemisphere. It is postulated to be caused by mutant Borrelia burgdorferi sensu lato spirochetes that assumed atypical pleomorphic forms and latent behavior in an attempt to adapt to the Brazilian ecosystem, explaining many particularities of the condition relative to the classical Lyme Disease, such as being transmitted by ticks others than those within the Ixodes ricinus complex, the difficulty culturing the etiological agent in traditional medium (BSK-II) and the poor growing of the spirochetes in atypical medium (SP-4), the frequent reactivations due to evading and surviving antibiotic treatment and eliciting low and transient immune response to Borrelia burgdorferi sensu lato antigens because of the hiding from the immune system.[2][3][4][5] The pleomorphic forms are thought to include round bodies resembling Chlamydia, non spiralled spirochete-like forms, blebs and cell wall deficient variants (L form bacteria) resembling Mycoplasma as seen in dark field microscopy and electron field microscopy searching bacteria in the blood of patients.[6] Spirochete-like structures are seen in around 90% of the patients when analyzing their peripheral blood in dark field microscopy.[7]

Presentation and symptoms

There is no universally agreed classification of all of the diverse presentations of the disease,[3][7] but Yoshinari et al. proposed that the condition features six distinct disease expressions:[3]

Localized acute infection

This stage includes flu-like symptoms and erythema migrans, the latter seen in 40-50% of the patients.[6][8][3]The expanding skin lesion follows a latent period after the inoculation ranging from 4 to 30 days, around 10 days on average, and it lasts from 3 days to 3 months, generally around 4 weeks.[3]

Early disseminate infection

Borrelia burgdorferi disseminates to various organs and tissues and patients can present clinically with symptoms as fever, enlarged lymph nodes, headaches,[9] chills, nausea and vomiting,[10] multiple anular EM-like lesions and, less commonly, borrelial lymphocytoma, a skin lesion typically associated with borrelia afzelii infection. Sometimes, other skin lesions can be found.[3][11][12]

Articular manifestations are found in around 40% of patients in the early disseminated stage, typically involving large joints such as the knee, presenting with considerable joint effusion. Arthritis lasts variable time amounts from a few weeks to a few months and resolves spontaneously. Analysis of the synovial fluid reveals inflammation and an elevated number of neutrophils.[3]It's also possible for recurrent arthritic flares to evolve into chronic articular manifestations similar to rheumatoid arthritis. These molest both small and large joints and present with morning stiffness.[3]

Neurological syndromes occur in around 35% of the patients in the early disseminated stage. Typically, it presents very similarly to the early triad of Lyme neuroborreliosis (LNB) manifestations and include cranial neuropathy,[13]radiculopathy and lymphonomononuclear meningitis. The cerebrospinal fluid analysis reveals elevated proteins, increased number of mononuclear cells and sometimes the development oligoclonal bands. Other less typical manifestations include weakness, ptosis, mydriasis, dysarthria and inflammatory myositis.[8][10] The diagnosis of BYS should be suggestive when bilateral cranial neuropathy is concomitant with meningitis.[3]

Another notable characteristic of early Baggio-Yoshinari Syndrome is the presence of ocular involvement, being present in 43.8% of patients with early BYS neurological symptoms, often associated with cranial nerve inflammation and radiculopathy. The most common complaints are ptosis, strabismus, Claude Bernard Syndrome, corneal reflex disturbance, ophthalmoparesis, anisocoria, mydriasis, neuroretinitis, papilledema, uveitis, retinal lesions, retinal arteritis, chorioretinitis, optic neuritis, diplopia and photophobia.[8][9][14]

Cardiac involvement is seen in less than 5% of the patients and it is clinically indistinguishable from Lyme Disease cardiac manifestations.[3] Most often these involve conduction system abnormalities, commonly presenting as an atrioventricular conduction block.[15]

Latent infection

Assays of PCR amplification works as a proof that Borrelia burgdorferi persist latently in the body of the patients just to reactivate later, causing the appearance of late stage and reactive manifestations. There are documented cases of PCR targeting the flgE gene in the synovial fluid and skin lesions of patients that were previously treated, sometimes extensively.[3]

Reactive disease expression resembling CFS/ME

Symptoms typical of CFS/ME are often found in BYS patients, with prevalences being around 50-60%.[16] CFS/ME is a syndrome that causes severe fatigue, cognitive dysfunction, post-exertional malaise, sleep disturbances, orthostatic intolerance and a myriad of other symptoms.[17]Manifestations that look like post-treatment Lyme disease syndrome (PTLDS) are also commonly present in BYS patients. PTLDS is currently classified as a post-infectious syndrome that occurs in a subset of patients.[18] Defining symptoms include impairing fatigue, musculoskeletal pain and neurocognitive dysfunction, but many others are often present, like sleep disturbances, paresthesia and autonomic dysfunction.[19][20] Its prevalence varies widely, with the 10-20% range being a common estimation for ideally-treated early Lyme disease patients at the 6-12 month follow-up evaluation.[21] PTLDS pathophysiology is still unclear, and proposed causes include persistent infection or debris, tissue damage, immune system dysfunction, autoimmunity and central sensitization.[22][23][24][25][26] Brain white matter alterations[27] and markers of microglial activation[28] were found in some studies. Treatment options are currently limited or controversial, as repeated antibiotic treatment has been found to be helpful in some trials[29][30] but not in others.[31] Recently, psilocybin-assisted treatment was tested in a pilot study with promising benefits for overall symptom burden, fatigue, mental and physical quality of life, depression, sensory and affective pain and sleep disturbances.[32][33] These manifestations happen most often in BYS patients who have not been treated or have undergone just a few days of treatment.[3]

Reactive disease expression resembling autoimmune or allergic diseases

As the disease progresses, some patients show clinical manifestations and laboratory signs of autoimmune or allergic diseases "which resemble Sjögren's syndrome; rheumatoid arthritis; inflammatory myositis similar to poly-dermatomyositis with increased muscle enzymes (creatine phosphokinase, aldolase) and electromyography alterations; panniculitis; localized scleroderma; venous thrombosis with antiphospholipid antibodies; clinical manifestations mimicking systemic lupus erythematosus such as Raynaud's phenomenon, alopecia and photosensitivity; sudden onset of drug or food allergies."[3]Laboratory abnormalities that are seen in autoimmune diseases can also be seen at these patients, including antinuclear antibodies, hypergammaglobulinemia, anticardiolipin antibodies and antineutrophil cytoplasmatic antibodies (ANCA) and elevated IgE.[3]

BYS patients may develop autoantibodies targeting skin and neural tissue. It was discovered that of early BYS patients, 30% test positive for antibodies against skin targets and 40% test positive against neural targets. For patients at the late stage, 38.4% test positive for antibodies against skin targets and 64.1% test positive for antibodies against neural targets. The difference in prevalence against neural targets when comparing early and late patients crossed the threshold for statistical significance.[3]

Unclassified disease expression

This isn't exactly a stage, but rather a category for patients whose manifestations doesn't fit neatly in the aforementioned stages. It usually includes patients with severe and unremitting neuropsychiatric manifestations that look alike autoimmune and infectious encephalitis.[3][34]

Distinctive characteristics

A distinctive feature of the syndrome is its prolonged clinical evolution, with relapsing episodes and autoimmune dysfunction. If diagnosed in its early stage, historically arbitrarily defined as less than 3 months after the inoculation, the symptoms respond well to antibiotics. If the disease progresses to the chronic phase, it can potentially cause chronic fatigue syndrome symptoms, autoimmune manifestations, arthritis, late neuroborreliosis and skin lesions such as acrodermatitis chronica atrophicans, erythema nodosum and reactive exantema, with the patient being at risk of developing both articular and neuropsychiatric sequelae.[4]

Neurological manifestations

The neurological manifestations of BYS were first described by Yoshinari et al., including patients with the classical neurological triad of early neuroborreliosis: Radiculoneuritis, meningitis, and cranial neuritis (facial nerve palsy, diplopia, and deafness).[8]"Nearly 30% of the patients (with neurological symptoms) show signs suggestive of encephalitis[3], these patients exhibit severe and repeated episodes of headaches, muscle fasciculations, loss of equilibrium, gait disturbances and cognitive changes."[3] Psychiatric and psychosocial manifestations even in patients without relevant psychiatric history are also a remarkable feature of Baggio-Yoshinari Syndrome neurological cases, seen in 12.5% of early BYS and in 28.5% of late BYS patients with neurological symptoms.[8] These include aggressive behavior, suicidal attempt, depression, panic attacks, hallucinations, paranoia, catatonia, obsessive compulsive disorder, anorexia and social disability.[8][3]Encephalomyelitis, defined as a progressive inflammatory involvement of the brain white matter, was found in 33.3% of the patients. Progression is typically insidious, and patients can develop cerebellar syndromes, spastic paraparesis, cerebellar ataxia (30%), organic psychiatric manifestations (60%), seizures (10%), hemiparesis, sphincter dysfunction (20%), movement disorders and transverse myelitis.[8] Notably, half of the patients within the encephalomyelitis group had early BYS.[8]Neurological manifestations can progress, and clinical pictures that resemble those of Guillain-Barre Syndrome, amyotrophic lateral sclerosis, multiple sclerosis and Parkinson's disease can take place during the disease evolution.[3] Follow-up care of patients with neurological symptoms revealed that 55.6% of patients with early BYS and 90% of patients with late BYS had episodes of recurrence, with the first relapse occurring months to years after the first treatment.[8]

Another relevant neurological manifestation is the development of chronic encephalopathy.[8]Lyme encephalopathy (LE) is a well-described, although somewhat controversial, late neurologic syndrome in the literature.[35][36][37]It typically presents months to many years after the initial Lyme disease manifestations, sometimes in patients who had been previously treated,[35] with symptoms as headaches, excessive daytime somnolence, depression, fatigue, sleep disturbances and cognitive deficits, most notably low verbal memory scores.[38][39][40][41]The CSF analysis of these patients often show intrathecal antibody synthesis, elevated protein levels, normal glucose and less commonly, pleocytosis. Caution is warranted, as sometimes the CSF is normal.[40] Often, an axonal sensorimotor radiculoneuropathy accompanies the syndrome.[35][42]Patients with LE display hypoperfusion of cerebral frontal subcortical and cortical structures on SPECT that can partially reverse after antibiotic treatment.[38]Patients with Lyme encephalopathy often do not respond fully to antibiotic treatment, typically IV ceftriaxone 2g/day for 2-4 weeks.[35][40]In a case series study by Logigian et al., at a follow-up evaluation conducted at 12-24 months after a 4 week course of IV ceftriaxone, while all had improved, only 39% of the patients considered themselves as "normal".[40] These results are even better than the ones from an earlier series, in which only 58% of the patients with encephalopathy showed sustained improvement at the 6 month follow-up examination after a shorter 2 week course of IV ceftriaxone.[35] Some authors consider the patients whose objective cognitive deficits persist after treatment to have post-treatment Lyme encephalopathy (PTLE).[30]These patients show cerebral hypoperfusion that is thought to be secondary to both metabolic and vascular factors, as seen on PET and SPECT scans, primarily in the temporal, parietal and limbic bilateral gray and white matter.[43] It is still controversial if these patients respond to additional antibiotic treatment.[44][45]In a series of patients with neurological symptoms of Baggio-Yoshinari Syndrome, encephalopathy was seen in 8 of 30 cases (26,7%).[8]

Comparison with STARI

Some features of BYS also resemble those found in the Southern tick-associated rash illness (STARI, also known as Master's Disease), which is found in the Southern United States. However, there are distinctive differences; e.g., Baggio-Yoshinari Syndrome cause systemic symptoms but STARI do not.[46]

Diagnosis

The diagnosis of the syndrome is based on a combination of three major and three minor parameters. The diagnosis should be made if a patient meets the criteria for three major parameters or two major and two minor parameters.[47]The criteria follows below:

Major parameters

  • Erythema migrans or systemic manifestations (arthritis, neurological abnormalities, cardiac involvement);
  • Positive serology for Borrelia burgdorferi (HCFMUSP criteria).

Minor parameters:

  • Relapsing symptoms;
  • Identification of spirochete-like structures by dark-field microscopy or Giemsa staining.

Serology

The serology is considered positive if the ELISA or the Western blot is positive, combination that occurs in 64.7% of patients.[3]False positives occur in 16% of the healthy controls.[3] The Western blot is interpreted with the HCFMUSP criteria that says that the test is positive if four IgG bands are positive, if two IgM bands are positive or if two IgG bands and one igM band is positive.[3][8]Sometimes, antibody synthesis is detected only in the cerebrospinal fluid.[10]

PCR assays

Since the discovery of a target, PCR tests have been used to identify Baggio-Yoshinari Syndrome patients, mainly targeting the flgE gene as it was found to return positive in 29.3% [48]of the samples and agreed with serological results. Recently, patients could be identified with PCR tests targeting the main flagellin gene (FlaB).[47]

Treatment

Baggio-Yoshinari Syndrome is primarily treated with antibiotics, generally the same used to treat Lyme Disease, but for an extended period.[3] For the early localized stage, the treatment consists of doxycycline 100 mg BID (primary choice), amoxicillin 500 mg 8/8h, azithromycin 500 mg once a day, or cefuroxime 500 mg BID.[3] Independently of the antibiotic choice, the treatment should be employed for 30 days.

For patients at the disseminated infection stage, treatment involves the use of the aforementioned drugs for three months, often followed by the use of hydroxychloroquine for at least six months, in an attempt to prevent and remediate immune complications.[3]

Treatment of rheumatic complications can require the use of disease-modifying medications, along with the use of corticosteroids and biologic treatments.[3]

For patients with neurological symptoms, 2g/day of ceftriaxone (primary choice) or penicillin 4 million unitis 4/4h used intravenously is often the cornerstone of the treatment, generally used for 30 days, followed by 60 days of doxycycline 100 mg BID (primary choice) or minocycline 100 mg BID in order to avoid subsequent relapsing episodes.[47] Unfortunately, treatment of BYS is frequently unsatisfactory, but relapsing episodes should still be treated, as it has been shown to shorten the duration of the episode.[8]

For patients with neurological manifestations whose encephalitic symptoms don't respond adequately to antibiotic treatment, gamma globulin or immunosuppressive agents can be administered intravenously in order to attempt to further the improvement of these patients.[3] Prudence is needed, as the use of immunosuppressive agents risks worsening the infectious manifestations.

History

In 1989, Brazilian researchers Professors Domingos Baggio (an entomologist from the Biomedical Sciences Institute of the University of São Paulo), Paulo Yasuda (a microbiologist from the same institute) and Natalino Hajime Yoshinari (a physician from the Rheumatology Department at University of São Paulo's Medical School) started research on Lyme disease in Brazil, by suggestion of Dr. Allen C. Steere. At that time, LD was almost unknown among Brazilian physicians. A brief review of Lyme disease was published in Brazilian journals of medicine, as well as recommendations on how to deliver samples of blood, cerebrospinal fluid or ticks to the laboratory of HCFMUSP.[49][3]

The first cases were identified in Brazil in 1992 by Dr. Alexandre de Almeida, a physician of the Institute of infectologia Emílio Ribas, in siblings from Cotia, São Paulo that developed symptoms as a erythema migrans, general flu-like symptoms and arthritis after being bitten by ticks. Western Blot and ELISA tests for antibodies against borrelia burgdorferi antigens were performed and both came positive. Although the symptoms were similar to those presented by Lyme Disease patients, the clinical and laboratory results were remarkably different. Ticks of the Ixodes ricinus complex were not found at the risk areas;[50] bacteria from the Borrelia burgdorferi sensu lato complex—that cause Lyme disease—were not found in biological fluids and tissues of the siblings.[3][49]

Blood analysis of the patients on electron microscopy exhibited non spiralled structures resembling microorganisms of the spirochaete phylum and the patients frequently relapsed if they were treated with short courses of antibiotics. Borrelia burgdorferi was never isolated in Brazil. For these reasons, the Brazilian zoonosis was considered a new disease and named Baggio–Yoshinari Syndrome (BYS), defined as an "Exotic and emerging Brazilian infectious disease, transmitted by ticks not belonging to the Ixodes ricinus complex, caused by latent spirochetes with atypical morphology, which originates LD-like symptoms, except for occurrence of relapsing episodes and auto-immune disorders".[7]

In the late 2000s molecular data enabled the researchers to classify the etiological agent as belonging to the Borrelia burgdorferi sensu lato complex. Elenice Mantovani was invited in an attempt to identify the etiological agent of BYS for her PhD thesis. It was successful, as a 329 bp fragment of the gene that synthesize the flagellar hook (flgE) was identified and discovered to show 99.4% homology when sequenced and compared with the Borrelia burgdorferi sensu stricto gene, differing in only two base pairs.[16][51]In that same occasion, it was demonstrated that the etiological agent can invade endothelial cells.[16] Furthermore, the same sequencing pattern seen in the patients was found in rhipicephalus ticks and in the peripheral blood of bovines, giving information about the transmission cycle of the disease.[51]

Another important contribution was made by Talhari et al., when the occurrence of borrelia burgdorferi sensu lato was detected by focus floating microscopy and specific immunochemistry methods searching the bacteria in skin lesions clinically and histopathologically compatible with erythema migrans.[52] However, isolation of the pathogen was unsuccessful.[52]

References

  1. ↑ Gonçalves DD, Carreira T, Nunes M, Benitez A, Lopes-Mori FM, Vidotto O, et al. (2013). "First record of Borrelia burgdorferi B31 strain in Dermacentor nitens ticks in the northern region of Parana (Brazil)". Brazilian Journal of Microbiology. 44 (3): 883–887. doi:10.1590/S1517-83822013000300035. ISSN 1517-8382. PMC 3910206. PMID 24516456.
  2. ↑ Miziara C, Serrano V, Yoshinari N (2018). "Passage of Borrelia burgdorferi through diverse Ixodid hard ticks causes distinct diseases: Lyme borreliosis and Baggio-Yoshinari syndrome". Clinics. 73 e394. doi:10.6061/clinics/2018/e394. PMC 6218955. PMID 30462754.
  3. 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 Yoshinari N, Bonoldi V, Bonin S, Falkingham E, Giusto T (9 August 2022). "The Current State of Knowledge on Baggio–Yoshinari Syndrome (Brazilian Lyme Disease-like Illness): Chronological Presentation of Historical and Scientific Events Observed over the Last 30 Years". Pathogens. 11 (8): 889. doi:10.3390/pathogens11080889. hdl:11368/3030381. PMC 9415174. PMID 36015013.
  4. 1 2 Neto NS, Gauditano G, Yoshinari NH (March 2014). "Chronic lymphomonocytic meningoencephalitis, oligoarthritis and erythema nodosum: report of Baggio- Yoshinari syndrome of long and relapsing evolution". Revista Brasileira de Reumatologia (English Edition). 54 (2): 148–151. doi:10.1016/j.rbre.2014.03.010.
  5. ↑ Yoshinari NH, Bonoldi VL (January–March 2019). "Heresias e dogmas sobre a síndrome de Baggio-Yoshinari". Revista Paulista de Reumatologia (in Brazilian Portuguese). 18 (1): 23–26. doi:10.46833/reumatologiasp.2019.18.1.23-26. Retrieved 3 August 2026.
  6. 1 2 Mantovani E, Costa IP, Gauditano G, Bonoldi VL, Higuchi ML, Yoshinari NH (April 2007). "Description of Lyme disease-like syndrome in Brazil. Is it a new tick borne disease or Lyme disease variation?". Brazilian Journal of Medical and Biological Research = Revista Brasileira de Pesquisas Medicas e Biologicas. 40 (4): 443–456. doi:10.1590/s0100-879x2007000400002. ISSN 0100-879X. PMID 17401487.
  7. 1 2 3 Yoshinari NH, Mantovani E, Bonoldi VL, Marangoni RG, Gauditano G (2010). "Brazilian lyme-like disease or baggio-yoshinari syndrome: exotic and emerging brazilian tick-borne zoonosis". Revista da Associação Médica Brasileira. 56 (3): 363–369. doi:10.1590/S0104-42302010000300025. ISSN 0104-4230. PMID 20676548.
  8. 1 2 3 4 5 6 7 8 9 10 11 12 13 Shinjo SK, Gauditano G, Marchiori PE, Bonoldi VL, Costa IP, Mantovani E, et al. (2009). "Neurological manifestations in Baggio-Yoshinari Syndrome (Brazilian Lyme disease-like syndrome)". Revista Brasileira de Reumatologia. 49: 492–505. doi:10.1590/S0482-50042009000500003. ISSN 0482-5004.
  9. 1 2 Kowacs PA, Martins RT, Piovesan EJ, Pinto MC, Yoshinari NH (2013). "Chronic unremitting headache associated with Lyme disease-like illness". Arquivos de Neuro-Psiquiatria. 71 (7): 470–473. doi:10.1590/0004-282X20130064. ISSN 0004-282X. PMID 23857618.
  10. 1 2 3 Gouveia EA, Alves MF, Mantovani E, Oyafuso LK, Bonoldi VL, Yoshinari NH (2010). "Profile of patients with Baggio-Yoshinari Syndrome admitted at "Instituto de Infectologia Emilio Ribas"". Revista do Instituto de Medicina Tropical de São Paulo. 52 (6): 297–303. doi:10.1590/S0036-46652010000600003. ISSN 1678-9946. PMID 21225212.
  11. ↑ Yoshinari N, Spolidorio M, Bonoldi VL, Sotto M (2007). "Lyme disease like syndrome associated lymphocytoma: first case report in Brazil". Clinics. 62 (4): 525–526. doi:10.1590/S1807-59322007000400020. ISSN 1807-5932. PMID 17823716.
  12. ↑ Levischi CE (September 2025). "Lyme Disease Causing Complex Bullous Lesions: A Case Report". Cureus. 17 (9) e92859. doi:10.7759/cureus.92859. ISSN 2168-8184. PMC 12542265. PMID 41133080.
  13. ↑ Levischi CE (November 2023). "Facial Paralysis Due to Brazilian Lyme Disease: A Case Report and Literature Review". Cureus. 15 (11) e48748. doi:10.7759/cureus.48748. ISSN 2168-8184. PMC 10718473. PMID 38094549.
  14. ↑ Rodrigues BE, Branco AB, Amaral BA, Franca MD, Loureiro TG (2017). "Optic neuritis and chorioretinitis as ocular manifestations of borreliosis in Brazil: three cases reported". Revista Brasileira de Oftalmologia. 76: 259–261. doi:10.5935/0034-7280.20170054. ISSN 0034-7280.
  15. ↑ Itaya ED, Monteiro DH, Itaya GC, Kong N, d'Avila A (2024). "Lyme Carditis: An Infectious Cause of Atrioventricular Block – A Case Report". Arquivos Brasileiros de Cardiologia. 121 (10) e20240301. doi:10.36660/abc.20240301i. ISSN 0066-782X. PMC 11634212. PMID 39570161.
  16. 1 2 3 Mantovani E (15 September 2010). Identificação do agente etiológico da Doença de Lyme-símile brasileira (Síndrome Baggio-Yoshinari) (tese de doutorado thesis) (in Brazilian Portuguese). Universidade de São Paulo.
  17. ↑ CDC (22 May 2024). "IOM 2015 Diagnostic Criteria". Myalgic Encephalomyelitis/Chronic Fatigue Syndrome. Retrieved 1 August 2026.
  18. ↑ Aucott JN, Crowder LA, Kortte KB (June 2013). "Development of a foundation for a case definition of post-treatment Lyme disease syndrome". International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases. 17 (6): e443–449. doi:10.1016/j.ijid.2013.01.008. ISSN 1878-3511. PMID 23462300.
  19. ↑ Aucott JN, Rebman AW, Crowder LA, Kortte KB (February 2013). "Post-treatment Lyme disease syndrome symptomatology and the impact on life functioning: is there something here?". Quality of Life Research: An International Journal of Quality of Life Aspects of Treatment, Care and Rehabilitation. 22 (1): 75–84. doi:10.1007/s11136-012-0126-6. ISSN 1573-2649. PMC 3548099. PMID 22294245.
  20. ↑ Adler BL, Chung T, Rowe PC, Aucott J (2024). "Dysautonomia following Lyme disease: a key component of post-treatment Lyme disease syndrome?". Frontiers in Neurology. 15 1344862. doi:10.3389/fneur.2024.1344862. ISSN 1664-2295. PMC 10883079. PMID 38390594.
  21. ↑ Aucott JN, Yang T, Yoon I, Powell D, Geller SA, Rebman AW (March 2022). "Risk of post-treatment Lyme disease in patients with ideally-treated early Lyme disease: A prospective cohort study". International Journal of Infectious Diseases: IJID: Official Publication of the International Society for Infectious Diseases. 116: 230–237. doi:10.1016/j.ijid.2022.01.033. ISSN 1878-3511. PMID 35066160.
  22. ↑ Reynolds W (12 May 2025). "Post-Treatment Lyme Disease Syndrome May Be Driven by Remnants of Infection". News Center. Feinberg School of Medicine. Retrieved 4 August 2026.
  23. ↑ Wester KE, Nwokeabia BC, Hassan R, Dunphy T, Osondu M, Wonders C, et al. (July 2024). "What Makes It Tick: Exploring the Mechanisms of Post-treatment Lyme Disease Syndrome". Cureus. 16 (7) e64987. doi:10.7759/cureus.64987. ISSN 2168-8184. PMC 11332314. PMID 39161484.
  24. ↑ Steere AC (1 May 2020). "Posttreatment Lyme disease syndromes: distinct pathogenesis caused by maladaptive host responses". The Journal of Clinical Investigation. 130 (5): 2148–2151. doi:10.1172/JCI138062. ISSN 1558-8238. PMC 7190968. PMID 32281948.
  25. ↑ Rebman AW, Aucott JN (25 February 2020). "Post-treatment Lyme Disease as a Model for Persistent Symptoms in Lyme Disease". Frontiers in Medicine. 7 57. doi:10.3389/fmed.2020.00057. ISSN 2296-858X. PMC 7052487. PMID 32161761.
  26. ↑ Batheja S, Nields JA, Landa A, Fallon BA (July 2013). "Post-Treatment Lyme Syndrome and Central Sensitization". The Journal of Neuropsychiatry and Clinical Neurosciences. 25 (3): 176–186. doi:10.1176/appi.neuropsych.12090223. PMID 24026711.
  27. ↑ Marvel CL, Alm KH, Bhattacharya D, Rebman AW, Bakker A, Morgan OP, et al. (2022). "A multimodal neuroimaging study of brain abnormalities and clinical correlates in post treatment Lyme disease". PLOS ONE. 17 (10) e0271425. Bibcode:2022PLoSO..1771425M. doi:10.1371/journal.pone.0271425. ISSN 1932-6203. PMC 9604010. PMID 36288329.
  28. ↑ Coughlin JM, Yang T, Rebman AW, Bechtold KT, Du Y, Mathews WB, et al. (19 December 2018). "Imaging glial activation in patients with post-treatment Lyme disease symptoms: a pilot study using [11C]DPA-713 PET". Journal of Neuroinflammation. 15 (1): 346. doi:10.1186/s12974-018-1381-4. ISSN 1742-2094. PMC 6299943. PMID 30567544.
  29. ↑ Krupp LB, Hyman LG, Grimson R, Coyle PK, Melville P, Ahnn S, et al. (24 June 2003). "Study and treatment of post Lyme disease (STOP-LD): a randomized double masked clinical trial". Neurology. 60 (12): 1923–1930. doi:10.1212/01.wnl.0000071227.23769.9e. ISSN 1526-632X. PMID 12821734.
  30. 1 2 Fallon BA, Keilp JG, Corbera KM, Petkova E, Britton CB, Dwyer E, et al. (25 March 2008). "A randomized, placebo-controlled trial of repeated IV antibiotic therapy for Lyme encephalopathy". Neurology. 70 (13): 992–1003. doi:10.1212/01.WNL.0000284604.61160.2d. ISSN 1526-632X. PMID 17928580.
  31. ↑ Klempner MS, Hu LT, Evans J, Schmid CH, Johnson GM, Trevino RP, et al. (2001). "Two Controlled Trials of Antibiotic Treatment in Patients with Persistent Symptoms and a History of Lyme Disease". The New England Journal of Medicine. 345 (2): 85–92. doi:10.1056/NEJM200107123450202. PMID 11450676.
  32. ↑ Garcia-Romeu A, Naudé GP, Rebman AW, So S, Yaffe A, Geithner I, et al. (25 February 2026). "Pilot study of psilocybin in patients with post-treatment lyme disease". Scientific Reports. 16 (1): 7497. Bibcode:2026NatSR..16.7497G. doi:10.1038/s41598-026-38091-9. ISSN 2045-2322. PMC 12936178. PMID 41741501.
  33. ↑ Garcia-Romeu A (2026). "Psilocybin administration impact on sleep continuity". Sleep. 49: A454. doi:10.1093/sleep/zsag091.1019.
  34. ↑ Lino AM, Spera RR, de Campos FP, Freitas CH, Garcia MR, Lopes Ld, et al. (2014). "Adult-onset opsoclonus-myoclonus-ataxia syndrome as a manifestation of brazilian lyme disease-like syndrome: a case report and review of literature". Autopsy & Case Reports. 4 (1): 29–37. doi:10.4322/acr.2014.005. ISSN 2236-1960. PMC 5470562. PMID 28652990.
  35. 1 2 3 4 5 Logigian EL, Kaplan RF, Steere AC (22 November 1990). "Chronic Neurologic Manifestations of Lyme Disease". New England Journal of Medicine. 323 (21): 1438–1444. doi:10.1056/NEJM199011223232102. ISSN 0028-4793. PMID 2172819.
  36. ↑ Fallon BA, Nields JA (November 1994). "Lyme disease: a neuropsychiatric illness". The American Journal of Psychiatry. 151 (11): 1571–1583. doi:10.1176/ajp.151.11.1571. ISSN 0002-953X. PMID 7943444.
  37. ↑ Halperin JJ (2014). "Nervous system Lyme disease". Neurologic Aspects of Systemic Disease Part III. Handbook of Clinical Neurology. Vol. 121. pp. 1473–1483. doi:10.1016/B978-0-7020-4088-7.00099-7. ISBN 978-0-7020-4088-7. ISSN 0072-9752. PMID 24365431.
  38. 1 2 Logigian EL, Johnson KA, Kijewski MF, Kaplan RF, Becker JA, Jones KJ, et al. (December 1997). "Reversible cerebral hypoperfusion in Lyme encephalopathy". Neurology. 49 (6): 1661–1670. doi:10.1212/wnl.49.6.1661. ISSN 0028-3878. PMID 9409364.
  39. ↑ Kaplan RF, Jones-Woodward L (March 1997). "Lyme encephalopathy: a neuropsychological perspective". Seminars in Neurology. 17 (1): 31–37. doi:10.1055/s-2008-1040910. ISSN 0271-8235. PMID 9166957.
  40. 1 2 3 4 Logigian EL, Kaplan RF, Steere AC (August 1999). "Successful treatment of Lyme encephalopathy with intravenous ceftriaxone". The Journal of Infectious Diseases. 180 (2): 377–383. doi:10.1086/314860. ISSN 0022-1899. PMID 10395852.
  41. ↑ Benke T, Gasse T, Hittmair-Delazer M, Schmutzhard E (May 1995). "Lyme encephalopathy: long-term neuropsychological deficits years after acute neuroborreliosis". Acta Neurologica Scandinavica. 91 (5): 353–357. doi:10.1111/j.1600-0404.1995.tb07020.x. ISSN 0001-6314. PMID 7639064.
  42. ↑ Logigian EL, Steere AC (February 1992). "Clinical and electrophysiologic findings in chronic neuropathy of Lyme disease". Neurology. 42 (2): 303–311. doi:10.1212/wnl.42.2.303. ISSN 0028-3878. PMID 1310529.
  43. ↑ Fallon BA, Lipkin RB, Corbera KM, Yu S, Nobler MS, Keilp JG, et al. (1 May 2009). "Regional Cerebral Blood Flow and Metabolic Rate in Persistent Lyme Encephalopathy". Archives of General Psychiatry. 66 (5): 554–563. doi:10.1001/archgenpsychiatry.2009.29. ISSN 0003-990X. PMID 19414715.
  44. ↑ Fallon BA, Petkova E, Keilp JG, Britton CB (2012). "A reappraisal of the u.s. Clinical trials of post-treatment lyme disease syndrome". The Open Neurology Journal. 6: 79–87. doi:10.2174/1874205X01206010079. ISSN 1874-205X. PMC 3474942. PMID 23091568.
  45. ↑ Klempner MS, Baker PJ, Shapiro ED, Marques A, Dattwyler RJ, Halperin JJ, et al. (1 August 2013). "Treatment Trials for Post-Lyme Disease Symptoms Revisited". The American Journal of Medicine. 126 (8): 665–669. doi:10.1016/j.amjmed.2013.02.014. ISSN 0002-9343. PMC 4075423. PMID 23764268.
  46. ↑ CDC (11 May 2026). "About Southern Tick-Associated Rash Illness". Southern Tick-Associated Rash Illness. Retrieved 3 August 2026.
  47. 1 2 3 Bonoldi VL, Yoshinari NH, Trevisan G, Bonin S (21 October 2024). "Baggio-Yoshinari Syndrome: A Report of Five Cases". Microorganisms. 12 (10): 2108. doi:10.3390/microorganisms12102108. ISSN 2076-2607. PMC 11510619. PMID 39458417.
  48. ↑ "DSpace". repositorio.ufms.br. Retrieved 2 August 2026.
  49. 1 2 Yoshinari NH (2009). "Uma longa jornada para entender a Borrelia burgdorferi no Brasil". Revista Brasileira de Reumatologia (in Portuguese). 49 (5): 483–484. doi:10.1590/S0482-50042009000500001. ISSN 0482-5004.
  50. ↑ Barros-Battesti DM (15 July 1998). Estudos de carrapatos e pequenos mamíferos silvestres naturalmente infectados com espiroquetas semelhantes à Borrelia, no município de Itapevi, Estado de São Paulo (tese de doutorado thesis) (in Brazilian Portuguese). Universidade de São Paulo.
  51. 1 2 Mantovani E, Marangoni RG, Gauditano G, Bonoldi VL, Yoshinari NH (2012). "Amplification of the flgE gene provides evidence for the existence of a Brazilian borreliosis". Revista do Instituto de Medicina Tropical de São Paulo. 54 (3): 153–158. doi:10.1590/S0036-46652012000300007. ISSN 1678-9946. PMID 22634887.
  52. 1 2 Talhari S, de Souza Santos MN, Talhari C, de Lima Ferreira LC, Silva RM, Zelger B, et al. (September 2010). "Borrelia Burgdorferi "sensu lato" in Brazil: Occurrence confirmed by immunohistochemistry and focus floating microscopy". Acta Tropica. 115 (3): 200–204. doi:10.1016/j.actatropica.2010.02.017. ISSN 0001-706X. PMID 20211144. Archived from the original on 18 June 2022.